Journal: Journal of the American Academy of Dermatology
Authors: Rebecca Persson, Katrina Wilcox Hagberg, Yiran Qian, Catherine Vasilakis-Scaramozza, Susan Jick
NLM Citation: Persson R, Hagberg KW, Qian Y, Vasilakis-Scaramozza C, Jick S. The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database. J Am Acad Dermatol. 2020 Jul;83(1):271-274. doi: 10.1016/j.jaad.2020.03.043. Epub 2020 Mar 25. PMID: 32222448.
To the Editor: The cardiovascular safety of apremilast is understudied.1,2 We conducted a study to quantify the risk of myocardial infarction, stroke, and revascularizations in people with apremilast-treated psoriasis compared with other systemic psoriasis treatments.
See this link for the full letter: https://www.jaad.org/article/S0190-9622(20)30463-1/fulltext
